Results 231 to 240 of about 28,054 (245)

[P3–070]: NOVEL ASSAYS FOR LRRK2 AND PS935 LRRK2

Alzheimer's & Dementia, 2017
Robert M. Umek, Amit Adhikari, Jill Dunty, Priya Ranganathan, Matthew Bess, Eugene Perelshteyn, Jacob N. Wohlstadter   +6 more
openaire   +1 more source

LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis

Proceedings of the National Academy of Sciences of the United States of America, 2018
Tomoya Eguchi, Tomoki Kuwahara, Genta Itô   +2 more
exaly  

Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice

Proceedings of the National Academy of Sciences of the United States of America, 2018
Yulan Xiong, Stewart Neifert, Senthilkumar S Karuppagounder   +2 more
exaly  

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers

Brain, 2018
Ye Zhao, Gayathri Perera, Deborah C Mash   +2 more
exaly  

The R1441C mutation of LRRK2 disrupts GTP hydrolysis

Biochemical and Biophysical Research Communications, 2007
Patrick A Lewis, Elisa Greggio, Alexandra Beilina   +2 more
exaly  

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice

Molecular Therapy - Nucleic Acids, 2020
Joanna A Korecka, Ria Thomas, Penelope J Hallett   +2 more
exaly  

LRRK2 phosphorylates novel tau epitopes and promotes tauopathy

Acta Neuropathologica, 2013
Jason P Covy, Heather L Melrose, Sarah Miles   +2 more
exaly  

Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration

Journal of Biological Chemistry, 2015
Laura A Volpicelli-Daley, Mark S Moehle, Stefanus J Steyn   +2 more
exaly  

Targeting LRRK2 in Parkinson’s disease: an update on recent developments

Expert Opinion on Therapeutic Targets, 2017
Eng-King Tan
exaly  

LRRK2gene variation and its contribution to Parkinson disease

Human Mutation, 2009
Coro Paisan-Ruiz
exaly